Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This little POS has legs.......
Ariad: You will most certainly want to see the new interviews on Ariad's home page of:
Dr. Zhu Video >
Dr. Kohlmann Video >
On Ponatinib.
Most definitely Dr. Kohlmann's interview..
You will most certainly want to see the new interviews on Ariad's home page of:
Dr. Zhu Video >
Dr. Kohlmann Video >
Most definitely Dr. Kohlmann interview..
When the ever bullish Peter on Rida became bearish, I knew it was game, set, match..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73488554
As long as Tim is in, I'm in...
Notice how smartly Harvey has lumped the two drugs from the past 19xx and Rida, seperately from the drugs of the future Pona and '113?
Will it hold??????????????
I hate to say this, but, stick a fork in it, it's done..
Harvey could sell ice to a family above the arctic circle.. That guy is that good..
And who, pray tell, paid for that piece?
This should move you closer:
http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2012.aspx
Neither of the last two posts to the abstracts works...
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): After reviewing the FDA’s briefing documents for ARIAD’s Taltorvic treatment for sarcoma, Rodman & Renshaw predicts that the panel’s decision on whether to recommend approving the drug will be “contentious”and “a squeaker.” The firm believes that the drug doesn’t provide major benefits to patients, but it also estimates that Taltorvic only represents $1 per share of value to ARIAD. The firm maintains an $18 target and Outperform rating on the stock.
Ouch..
Ridaforolimus treatment was also associated with a statistically significant mean target lesion size reduction of 1.3% compared to a mean target lesion size increase of 10.3 % with placebo..
I could work with this..
The reversal today tells you all you need to know...sweet.
Revised cash reserve guidance and another secondary in the second half of 2012. Oh well....
Barclay's has a note out:
title is "FDA Briefing Document Does Not Bode Well for Ridaforolimus." Said FDA analyis concludes a smaller PFS benefit than MRK/ARIA's analysis...15% improvement. Risk/Benefit not favorable. barclays expects ARIA to trade down slightly but woudl be buyers on the weakness because in their model, ridaforolimus contributes only peak $85 million revenues and $19 million royalties to ARIA or 2% of its valuation. They remain optimistic about the prospects for ponatinib.
This is way too small to effect MRK's share price..
The difference is Ariad/MRK 2-3 weeks vs Glaxo- 3 months. As good as it gets.. Thank the good Lord that not many individuals are effected by this condition..
The Merck study showed patients on ridaforolimus had a median progression-free survival of 17.7 weeks compared with 14.6 weeks for patients on the placebo, or a difference of about three weeks. An FDA analysis of that study, however, suggested the difference was about two weeks.
The study involving Glaxo's Votrient showed patients being treated with that drug had a median progression-free survival of 4.6 months compared with 1.6 months on the placebo, or a difference of three months.
Neither study showed a statistically significant difference in overall survival but it also wasn't the main goal of either study.
Glaxo's Sarcoma drug also under review next week..better profile than Rida..
News for 'ARIA' - (DJ FDA Panel To Review Merck, Glaxo Drugs For Soft-Tissue Sarcoma)
By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--The Food and Drug Administration on Friday questioned whether the benefit of using Merck & Co.'s (MRK) experimental cancer drug ridaforolimus in patients with soft-tissue or bone sarcomas was strong enough to offset the drug's side effects.
Merck is seeking FDA approval for use of ridaforolimus, a tablet, for use as a maintenance therapy in certain patients with soft-tissue or bone sarcomas who had been previously treated with chemotherapy. The sarcomas are a rare type of cancer that start in bone, muscle or other connective tissues in the body.
GlaxoSmithKline PLC (GSK, GSK.LN) is also seeking approval of its cancer drug Votrient for use in treating soft-tissue sarcoma. Votrient, also a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer.
Both drugs will be reviewed next Tuesday by the FDA's oncologic drugs advisory committee, which is made up of non-FDA medical experts. The FDA released reviews of both drugs on Friday. The panel will be asked to make recommendations on whether the products should be approved. The FDA is not required to follow its panel's advice but usually does so.
Separate studies involving Merck's and Glaxo's drugs compared them with placebos, or fake drugs. The studies were designed to look at a measure called progression-free survival, which is the time before cancer starts growing again.
The Merck study showed patients on ridaforolimus had a median progression-free survival of 17.7 weeks compared with 14.6 weeks for patients on the placebo, or a difference of about three weeks. An FDA analysis of that study, however, suggested the difference was about two weeks.
The study involving Glaxo's Votrient showed patients being treated with that drug had a median progression-free survival of 4.6 months compared with 1.6 months on the placebo, or a difference of three months.
Neither study showed a statistically significant difference in overall survival but it also wasn't the main goal of either study.
The FDA said the progression-free survival difference in the Merck study was "small" and questioned whether that difference was meaningful given the drug's side effects that include infection, rash and in some cases kidney damage.
Eric Rubin, a Merck vice president, explained that there's currently no approved maintenance therapy for soft-tissue and bone sarcomas and said chemotherapy often needs to be stopped after a certain number of treatments because of concerns about heart damage.
In a document prepared for Tuesday's meeting Merck said ridaforolimus resulted in a "reduction in the risk of disease progression."
Ridaforolimus, which Merck is proposing to sell under the brand name Taltorvic, was initially developed by Ariad Pharmaceuticals Inc. (ARIA). Merck bought the rights to finish development of Taltorvic, which targets a protein called mTOR that is involved in cancer growth. Glaxo's Votrient works by attacking another protein, tyrosine kinase, which is also involved with cancer tumor growth as well as blood vessels that help tumors grow.
The National Cancer Institute estimates there about 11,000 cases of soft-tissue sarcomas diagnosed each year and about 3,000 cases of bone sarcoma.
-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com
(END) Dow Jones Newswires
March 16, 2012 09:24 ET (13:24 GMT)
Copyright (c) 2012 Dow Jones & Company, Inc.- - 09 24 AM EDT 03-16-12
FDA Briefing Document on Ridaforolimus:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM296304.pdf
Given the small differences in median PFS and OS between arms, the adverse event profile of ridaforolimus, and its positioning as a maintenance therapy in patients with soft tissue and bone sarcoma, is the risk-benefit assessment favorable for the use of ridaforolimus in the treatment of patients with soft tissue and bone sarcoma who have received prior chemotherapy?
Stifel Nicolaus is just a tad late. Oh well, better late than never..
Thanks rkrw. Your piece from MD Anderson on Ph-positive ALL, and the note on the Silicon Investor web site dealing with Pona in solid tumors indicates to me that we have just begun to develop the Ponatinib franchise..
Bullish? He aquired 160,000 shares at $0 cost, and sold 66,800 at $14.95. I'll let you do the math.. There is nothing negative in what he did, but I don't think I would raise the "bullish" flag quite yet..
I remember an antibiotic drug that also met all it's endpoints for moderate CAP, however, it was not "robust" enough according to the FDA and was not approved. There is most definately some subjective decisions with this stuff..
From February 6th, lower highs and lower lows, I just feel a little uncomfortable here. I also have seen the FDA Advisory panels be too far "out there" in their discussions that can have an impact on the share price. I assure you the chance of a negative outcome on the 20th is not zero.. Plus, there are 3 or 4 sarcoma drugs right behind Rida in the clinicals right now.. Hope I wrong in my concerns, of course....
gdollar, unless you hold zero shares of Ariad, you are a betting man.
You will have to be quick with your Ariad purchase if negative news as this should be well known by now..
Could this be selling off because of Rida? It is not a strong candidate for approval, imho.. X weeks PFS gives me the willies.. This is the ONLY thing I worry about with Ariad..
Completely liquidated my position in IMUC today.. Nice ride..
Trust somebody, this is not over..
The question will be does Israel move before the election? I think they will, after Iran lets in the EU inspectors one more time, and then turns them away again..
Ariad is correcting BECAUSE of the SP
Everyone is looking for a 5% correction in the s&p, an analyist on Bloomberg this AM claimed we would be at 1700 on the s&p b4 EOy.. All bs. We need at least 10% off.
Crushed..